Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86185
Title:
Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma.
Authors:
Yao, Yunhong; Minter, Helena A; Chen, Xiaoyi; Reynolds, Gary M; Bromley, Michael; Arrand, John R
Abstract:
Nasopharyngeal carcinoma (NPC) is an aggressive tumour of multifactorial aetiology that, although rare in most parts of the world, poses a significant mortality problem in its high incidence area of Southern China. Improved therapies are an urgent requirement and, towards this end, immunotherapeutic methods are being developed in several centres. Such strategies are dependent on the immune competence of the target tumour, in particular its expression of HLA class-I. We examined HLA class-I and -II expression in 27 primary NPC biopsies and found that 15% were extensively down-regulated for class-I expression with the majority of tumour cells appearing negative. Whilst HLA class-II was expressed at high levels in the majority of tumours, 37% showed substantial down-regulation. NPC is associated with Epstein-Barr virus (EBV). Expression of the virus-encoded EBER RNAs is accepted as a marker of EBV latency and is regarded as a valuable diagnostic criterion. EBER RNAs were expressed in all samples, but in some the level was remarkably heterogeneous, being barely detectable in many tumour cells. Our study reinforces the concept of extensive phenotypic variation in NPC. There are morphological differences between tumour cells. Some tumours express HLA class-I and/or -II, whilst others are down-regulated or negative. Individual tumours may or may not express the EBV-encoded LMP-1 protein, and individual tumour cells may express high levels of EBER, yet adjacent tumour cells express very little or none.
Affiliation:
Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom.
Citation:
Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. 2000, 88 (6):949-55 Int. J. Cancer
Journal:
International Journal of Cancer
Issue Date:
15-Dec-2000
URI:
http://hdl.handle.net/10541/86185
DOI:
10.1002/1097-0215(20001215)88:6<949::AID-IJC18>3.0.CO;2-6
PubMed ID:
11093820
Type:
Article
Language:
en
ISSN:
0020-7136
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorYao, Yunhongen
dc.contributor.authorMinter, Helena Aen
dc.contributor.authorChen, Xiaoyien
dc.contributor.authorReynolds, Gary Men
dc.contributor.authorBromley, Michaelen
dc.contributor.authorArrand, John Ren
dc.date.accessioned2009-11-13T15:16:30Z-
dc.date.available2009-11-13T15:16:30Z-
dc.date.issued2000-12-15-
dc.identifier.citationHeterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. 2000, 88 (6):949-55 Int. J. Canceren
dc.identifier.issn0020-7136-
dc.identifier.pmid11093820-
dc.identifier.doi10.1002/1097-0215(20001215)88:6<949::AID-IJC18>3.0.CO;2-6-
dc.identifier.urihttp://hdl.handle.net/10541/86185-
dc.description.abstractNasopharyngeal carcinoma (NPC) is an aggressive tumour of multifactorial aetiology that, although rare in most parts of the world, poses a significant mortality problem in its high incidence area of Southern China. Improved therapies are an urgent requirement and, towards this end, immunotherapeutic methods are being developed in several centres. Such strategies are dependent on the immune competence of the target tumour, in particular its expression of HLA class-I. We examined HLA class-I and -II expression in 27 primary NPC biopsies and found that 15% were extensively down-regulated for class-I expression with the majority of tumour cells appearing negative. Whilst HLA class-II was expressed at high levels in the majority of tumours, 37% showed substantial down-regulation. NPC is associated with Epstein-Barr virus (EBV). Expression of the virus-encoded EBER RNAs is accepted as a marker of EBV latency and is regarded as a valuable diagnostic criterion. EBER RNAs were expressed in all samples, but in some the level was remarkably heterogeneous, being barely detectable in many tumour cells. Our study reinforces the concept of extensive phenotypic variation in NPC. There are morphological differences between tumour cells. Some tumours express HLA class-I and/or -II, whilst others are down-regulated or negative. Individual tumours may or may not express the EBV-encoded LMP-1 protein, and individual tumour cells may express high levels of EBER, yet adjacent tumour cells express very little or none.en
dc.language.isoenen
dc.subjectCancer Proteinsen
dc.subjectNasopharyngeal Canceren
dc.subject.meshAdult-
dc.subject.meshCarcinoma-
dc.subject.meshChina-
dc.subject.meshDown-Regulation-
dc.subject.meshFemale-
dc.subject.meshHerpesvirus 4, Human-
dc.subject.meshHistocompatibility Antigens Class I-
dc.subject.meshHistocompatibility Antigens Class II-
dc.subject.meshHumans-
dc.subject.meshIn Situ Hybridization-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNasopharyngeal Neoplasms-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshRNA-Binding Proteins-
dc.subject.meshRibosomal Proteins-
dc.subject.meshViral Matrix Proteins-
dc.titleHeterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom.en
dc.identifier.journalInternational Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.